drugset / Trial / NCT02481934
Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple Myeloma
Phase 1
Completed
5 enrolled
Joaquín Martínez López, MD, PhD
Hospital Infantil Universitario Niño Jesús, Madrid, Spain · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine wether activated and expanded autologous Natural Killer cells (NKAEs) are effective in the treatment of patients with multiple myeloma on second or later relapse. NKAEs are used in combination with anti-myeloma drugs such as lenalidomide or bortezomib.
Timeline
- Start
- 2013-03
- Primary completion
- 2016-07
- Completion
- 2016-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Bortezomib | Small molecule | 1.3 mg/m2 | Subcutaneous |
| Background | Lenalidomide | Other / unclassified | 10 mg | Oral |